Current Atherosclerosis Reports

, Volume 8, Issue 4, pp 310–316 | Cite as

Cardioembolic stroke

Article

Abstract

Cardiac sources of emboli account for over one quarter of all ischemic strokes. Strokes due to cardioembolism are in general severe and prone to early and long-term recurrence. Nonvalvular atrial fibrillation remains the most common cause of cardioembolic stroke. Despite the proven efficacy of oral anticoagulation, it is prescribed for less than half of the patients with risk factors for embolism and no contraindications for anticoagulation. The embolic risk of patent foramen ovale is low except when combined with an atrial septal aneurysm. Aortic arch atheroma as an independent risk factor for ischemic stroke is the subject of ongoing debate. As the risk of embolism is heterogeneous for the various potential cardioembolic conditions, accurate definition of stroke mechanism is very important to guide the most effective therapy.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Cardiogenic brain embolism: The second report of the Cerebral Embolism Task Force. Arch Neurol 1989, 46:727–743.Google Scholar
  2. 2.
    Grau AJ, Weimar C, Buggle F, et al.: Risk factors, outcome and treatment in subtypes of ischemic stroke. the German Stroke Data Bank. Stroke 2001, 32:2559–2566.PubMedGoogle Scholar
  3. 3.
    Eriksson SE, Olsson JE: Survival and recurrent strokes in people with different subtypes of stroke: a fourteen-year follow-up study. Cerebrovasc Dis 2001, 12:171–180.PubMedCrossRefGoogle Scholar
  4. 4.
    Kolominsky-Rabas PL, Weber M, Gefeller O, et al.: Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population based study. Stroke 2001, 32:2735–2740.PubMedGoogle Scholar
  5. 5.
    Arboix A, Oliveres M, Massons J, et al.: Early differentiation of cardioembolic from atherothrombotic cerebral infarction: a multivariate analysis. Eur J Neurol 1999, 6:677–683.PubMedCrossRefGoogle Scholar
  6. 6.
    Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991, 22:983–988.PubMedGoogle Scholar
  7. 7.
    Wyse DG, Waldo AL, DiMarco JP, et al.: The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347:1825–1833.PubMedCrossRefGoogle Scholar
  8. 8.
    Yamanouchi H, Nagura H, Mizutani T, et al.: Embolic brain infarction in nonrheumatic atrial fibrillation: a clinicopathologic study in the elderly. Neurology 1997, 48:1593–1597.PubMedGoogle Scholar
  9. 9.
    The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography: Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann Intern Med 1998, 128:639–647.Google Scholar
  10. 10.
    Stollenberger C, Chnupa P, Kronik G, et al.: Transesophageal echocardiography to access embolic risk in patients with atrial fibrillation. Ann Intern Med 1998, 128:630–638.Google Scholar
  11. 11.
    Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994, 154:1449–1457.CrossRefGoogle Scholar
  12. 12.
    Frykman V, Beerman B, Ryden L, Rosenqvist M: Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications. Eur Heart J 2001, 22:1954–1959.PubMedCrossRefGoogle Scholar
  13. 13.
    Go AS, Hylek EM, Borowsky LH, et al.: Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999, 131:927–934.PubMedGoogle Scholar
  14. 14.
    Olsson SB; Executive Steering Committee on behalf SPORTIF III Investigators: Stroke Prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet 2003, 362:1691–1698.PubMedCrossRefGoogle Scholar
  15. 15.
    Lorenzoni R, Lazzerini G, Cocci F, De Caterina R: Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) Pilot Study. Am Heart J 2004, 148:e6.Google Scholar
  16. 16.
    Pérez-Gómez F, Alegría E, Berjón J, et al.; NASPEAF Investigators: Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation. J Am Coll Cardiol 2004, 44:1557–1566.PubMedCrossRefGoogle Scholar
  17. 17.
    Gullov AL, Koefoed BG, Peterson P, et al.: Fixed minidose warfarin and aspirin alone and in combination vs adjusted dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulant Study. Arch Intern Med 1998, 158:1513–1521.PubMedCrossRefGoogle Scholar
  18. 18.
    Adjusted-dose warfarin versus low-intensity, fixed dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet 1996, 348:633–638.Google Scholar
  19. 19.
    Ostermayer SH, Reisman M, Kramer PH, et al.: Percutaneous left atrial appendage transcatheter occlusion (PLAATO System) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the International multi-center feasibility trials. J Am Coll Cardiol 2005, 46:9–14.PubMedCrossRefGoogle Scholar
  20. 20.
    Sick PB, Ulrich M, Hauptmann KE: Stroke prevention technology for patients with non-valvular AF-worldwide experience with the new WATCHMAN LAA system. J Am Coll Cardiol 2006, 47 (Suppl A):1015–1143.Google Scholar
  21. 21.
    Beyth RJ, Quinn L, Landefeld CS: A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized controlled trial. Ann Intern Med 2000, 133:687–695.PubMedGoogle Scholar
  22. 22.
    Amarenco P, Cohen A, Tzourio C, et al.: Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med 1994, 331:1474–1479.PubMedCrossRefGoogle Scholar
  23. 23.
    Amarenco P, Duyckaerts C, Tzourio C, et al.: The prevalence of ulcerated plaques in the aortic arch in patients with stroke. N Engl J Med 1992, 326:221–225.PubMedCrossRefGoogle Scholar
  24. 24.
    Meissner I, Khandheria BK, Sheps SG, et al.: Aorta: Risk factors, risk marker, or innocent bystander?: A prospective population-based transesophagaal study. J Am Coll Cardiol 2004, 44:1018–1024.PubMedCrossRefGoogle Scholar
  25. 25.
    Ferrari E, Vidal R, Chevallier T, Baudouy M: Atherosclerosis of the thoracic aorta and aortic debris as a marker of poor prognosis: benefit of oral anticoagulants. J Am Coll Cardiol 1999, 33:1317–1322.PubMedCrossRefGoogle Scholar
  26. 26.
    Blackshear AJ, Zabalgoitia M, Pennock G, et al.; on behalf of the SPAF TEE Investigators: Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation. Am J Cardiol 1999, 83:453–455.PubMedCrossRefGoogle Scholar
  27. 27.
    Mohr J, Thompson JL, Lazar RM, et al.; for the Warfarin-Aspirin Recurrent Stroke Study Group: A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001, 345:1444–1451.PubMedCrossRefGoogle Scholar
  28. 28.
    Donnan GA: Aortic Arch Related Cerebral Hazard (ARCH). The American Stroke Association 28th International Stroke Conference. Phoenix, AZ, February 2003, 2005.Google Scholar
  29. 29.
    Tunick PA, Nayar AC, Goodkin GM, et al.: Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque. Am J Cardiol 2002, 90:1320–1325.PubMedCrossRefGoogle Scholar
  30. 30.
    Loh E, Sutton MS, Wun CC, et al.: Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997, 47:71–84.Google Scholar
  31. 31.
    van Es RF, Jonker JJ, Verheugt FW, et al.; for the Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) Research Group: Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomized controlled trial. Lancet 2002, 360:109–113.PubMedCrossRefGoogle Scholar
  32. 32.
    LaPeyre AC, Steele PM, Kazmier FS, et al.: Systemic embolization in chronic left ventricular aneurysm: incidence and role of anticoagulation. J Am Coll Cardiol 1985, 6:534–538.PubMedCrossRefGoogle Scholar
  33. 33.
    Pullicino PM, Halperin JL, Thompson JL: Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology 2000, 54:288–294.PubMedGoogle Scholar
  34. 34.
    Sacco RL, Adams R, Albers G, et al.: Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guidelinne. Stroke 2006, 37:577–617.PubMedCrossRefGoogle Scholar
  35. 35.
    Albers GW, Amarenco P, Easton JD, et al.: Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126:483–512.CrossRefGoogle Scholar
  36. 36.
    Barnett HJ, Boughner DR, Taylor DW, et al.: Further evidence regarding mitral-valve prolapse to ischemic events. N Engl J Med 1980, 302:139–144.PubMedCrossRefGoogle Scholar
  37. 37.
    Gilon D, Buonanno FS, Joffe MM, et al.: Lack of evidence of an association between mitral-valve prolapse and stroke in young adults. N Engl J Med 1999, 341:8–13.PubMedCrossRefGoogle Scholar
  38. 38.
    Benjamin EJ, Plehn JF, D’Agostino RB, et al.: Mitral annular calcification and the risk of stroke in an elderly cohort. N Engl J Med 1992, 327:374–379.PubMedCrossRefGoogle Scholar
  39. 39.
    Kizer JR, Wiebers DO, Whisnant JP, et al.: Mitral annular calcification, aortic valve sclerosis, and incident stroke in adults free of clinical cardiovascular disease: the Strong Heart Study. Stroke 2005, 36:2533–2537.PubMedCrossRefGoogle Scholar
  40. 40.
    Borowski A, Ghodsizad A, Cohnen M, Gams E: Recurrent embolism in the course of marantic endocarditis. Ann Thorac Surg. 2005, 79:2145–2147.PubMedCrossRefGoogle Scholar
  41. 41.
    Tornos P, Almirante B, Mirabet S, et al.: Infective endocarditis due to Staphylococcus aureus-deleterious effect of anticoagulant therapy. Arch Int Med 1999, 159:423–475.CrossRefGoogle Scholar
  42. 42.
    Bayer AS, Bolger AF, Taubert KA, et al.: Diagnosis and management of infective endocarditis and its complications. AHA Scientific Statement. Circulation 1998, 98:2936–2948.PubMedGoogle Scholar
  43. 43.
    Fairfax AJ, Lambert CD, Leatham A: Systemic embolism in chronic sinoatrial disorder. N Engl J Med 1976, 295:190–192.PubMedCrossRefGoogle Scholar
  44. 44.
    Lechat P, Mas JL, Lascault G, et al.: Prevalence of patent forament ovale in patients with stroke. N Engl J Med 1988, 318:1148–1152.PubMedCrossRefGoogle Scholar
  45. 45.
    Petty GW, Khandheria BK, Chu CP, et al.: Patent foramen ovale in patients with cerebral infarction: a transesophageal echocardiographic study. Arch Neurol 1997, 54:819–822.PubMedGoogle Scholar
  46. 46.
    Cabanes L, Mas JL, Cohen A, et al.: Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age. A study using transesophageal echocardiography. Stroke 1993, 24:1865–1873.PubMedGoogle Scholar
  47. 47.
    Mas JL, Arquizan C, Lamy C, et al.; for the Patent Foramen Ovale and Atrial Septal Aneurysm Study Group: Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001, 345:1740–1746.PubMedCrossRefGoogle Scholar
  48. 48.
    Homma S, Sacco RL, Di Tullio MR, et al.: Effect of medical treatment in patients with patent foramen ovale: patent foramen ovale in cryptogenic stroke study (PICSS). Circulation 2002, 105:2625–2631.PubMedCrossRefGoogle Scholar
  49. 49.
    Messe SR, Silverman IE, Kiser JR, et al.: Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm. Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2004, 62:1042–1050.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.Internal Medicine/Cardiovascular MedicineUniversity of Texas Health Science CenterHoustonUSA

Personalised recommendations